Liquid chromatography method for quantifying d-threo-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (d-threo-PPMP) in mouse plasma and liver

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 837, Issue 1-2, 2006, Pages 44-48

  Wu, Xiaqin ^a   Kim, Youngleem ^a   Sun, Bee Chun ^a   Moore, Jeff D ^b   Shaw, Walter A ^b   Maurer, Barry J ^a,c  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b Avanti Polar Lipids Inc   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

D threo PPMP; HPLC

Indexed keywords

ASSAYS; BIOLOGICAL ORGANS; CONCENTRATION (PROCESS); HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PLASMAS; POTASSIUM;

BIOAVAILABILITY; D-THREO-PPMP; LUNA PHENY-HEXYL COLUMN (; MOUSE PLASMA;

ALCOHOLS;

ACETONITRILE DERIVATIVE; BUFFER; DEXTRO THREO 1 PHENYL 2 PALMITOYLAMINO 3 MORPHOLINO 1 PROPANOL; ENZYME INHIBITOR; POTASSIUM DIHYDROGEN PHOSPHATE; UNCLASSIFIED DRUG;

ACCURACY; ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOAVAILABILITY; CALIBRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; EXTRACTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER; MOUSE; NONHUMAN; PLASMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STANDARD; ULTRAVIOLET SPECTROSCOPY;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; LIVER; MICE; MICE, INBRED BALB C; MORPHOLINES; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPHINGOLIPIDS;

EID: 33646866968     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2006.03.060     Document Type: Article

References (16)

1. Abe A., Radin N.S., Shayman J.A., Wotring L.L., Zipkin R.E., Sivakumar R., Ruggeiri J.M., Carson K.G., and Ganem B. J. Lipid. Res. 36 (1995) 611
2. Abe A., Inokuchi J., Jimbo M., Shimeno H., Nagamatsu A., Shayman J.A., Shukla G.S., and Radin N.S. J. Biochem. (Tokyo) 111 (1992) 191
3. Abe A., Shayman J.A., and Radin N.S. J. Biol. Chem. 271 (1996) 14383
4. Reynolds C.P., Maurer B.J., and Kolesnick R. Cancer Lett. 206 (2004) 169
5. Maurer B.J., Metelitsa L.S., Seeger R.C., Cabot M.C., and Reynolds C.P. J. Natl. Cancer Inst. 91 (1999) 1138
6. Batra S., Reynolds C.P., and Maurer B.J. Cancer Res. (2004) 5415
7. Maurer B.J., Melton L., Billups C., Cabot M.C., and Reynolds C.P. J. Natl. Cancer Inst. 92 (2000) 1897
8. O'Donnell P.H., Guo W.X., Reynolds C.P., and Maurer B.J. Leukemia 16 (2002) 902
9. Wang H., and Maurer B.J. Proc. Amer. Assoc. Can. Res. 46 (2005) 1174
10. Cox T.M. Acta Paediatr. Suppl. 94 (2005) 69
11. Jmoudiak M., and Futerman A.H. Br. J. Haematol. 129 (2005) 178
12. Snyder L.R., Kirkland J.J., and Glajch J.L. Practical HPLC Method Development (1997), John Wiley & Sons Inc., New York, NY p. 685
13. Figg W.D., and McLeod H.L. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics (2004), Humana Press Inc., Totowa, NJ p. 91
14. Center for Drug Evaluation and Research (CDER) and Center for Veterinary Medicine (CVM). Guidance for Industry, Bioanalytical Method Validation, Rockville, MD, U.S. Food and Drug Administration, U.S. Department of Health and Human Services, 2001.
15. Bleicher R.J., and Cabot M.C. Biochem. Biophys. Acta 1585 (2002) 172
16. Gouaze V., Yu J.Y., Bleicher R.J., Han T.Y., Liu Y.Y., Wang H., Gottesman M.M., Bitterman A., Giuliano A.E., and Cabot M.C. Mol. Cancer Ther. 3 (2004) 633